Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01227408
Recruitment Status : Withdrawn (Sponsor withdrew due to funding issues)
First Posted : October 25, 2010
Last Update Posted : May 2, 2017
CTI BioPharma
Information provided by (Responsible Party):
University of Southern California

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
  Recruitment Status : Withdrawn
  Estimated Primary Completion Date : February 2010
  Estimated Study Completion Date : February 2011